Drug Delivery System– tag –
-
Drug Discovery & DDS Weekly Report June 28, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report June 28, 2026 (PDF) — Download Weekly Report June 28, 2026 (PDF) — DownloadDownload 🎙 Podcast June 28, 2026 (... -
Exosomes: Unlocking Nature’s Nanoparticles for Precision Medicine, Navigating Translational Hurdles
Frontiers (論文) Global Overview Exosome research is rapidly advancing, revealing substantial potential in drug delivery and regenerative medicine due to their inherent biocompatibility and targeting capabilities. However, clinical trans... -
Drug Discovery & DDS Weekly Report May 20, 2026
▼ ▼ ▼ If you found the infographic compelling and want to read the full Weekly Report, click below to download the Strategy Report. ▼ ▼ ▼ 📄 Drug Discovery & DDS Weekly Report — June 20, 2026 DrugDiscovery_DDS_WeeklyReport_EN_20260620.pd... -
University of Houston Discovers ‘Salt-Loaded LNPs’ to Overcome Major Gene Therapy Obstacle by Enhancing Endosomal Escape
University of Houston USA Overview Researchers at the University of Houston have made a groundbreaking discovery to improve intracellular delivery of genetic material, a major hurdle in gene therapy. They developed 'salt-loaded lipid nan... -
Drug Discovery & DDS Weekly Report May 13, 2026
📄 Weekly Report June 13, 2026 (PDF) — Download Weekly Report June 13, 2026 (PDF) — DownloadDownload 🎙 Podcast June 13, 2026 (MP3) — Play & Download DrugDiscovery_DDSEnglishPodcast_20260613.mp3Download View Past Weekly Reports→ -
FDA Streamlines Nonclinical Studies for Biologics and Conjugated Products, Accepting NAMs for ADCs to Reduce Non-Human Primate Use
FDA USA Overview The FDA's Center for Drug Evaluation and Research (CDER) is streamlining nonclinical studies for biologics and conjugated products, including Antibody-Drug Conjugates (ADCs) and CD3 bispecific T-cell engagers. For ADCs w... -
FDA Approves Oral Peptide Icorokinra for Moderate-to-Severe Plaque Psoriasis, Driven by Advanced DDS
Dermatology Times USA Overview The FDA has approved icorokinra, the first oral IL-23 receptor antagonist peptide for moderate-to-severe plaque psoriasis, representing a significant breakthrough in oral peptide delivery systems (DDS). Thi... -
Drug Discovery & DDS Weekly Report May 7, 2026
📄 Weekly Report June 07, 2026 (PDF) — Download Weekly Report June 07, 2026 (PDF) — DownloadDownload 🎙 Podcast June 07, 2026 (MP3) — Play & Download DrugDiscovery_DDSEnglishPodcast_20260607.mp3Download View Past Weekly Reports→ -
Oral Peptide Therapeutics Gain Traction in Dermatology, SNAC Technology Offers New Possibilities for Psoriasis Treatment
MedCentral Unknown Overview Oral peptide therapeutics are gaining significant attention in dermatology, particularly for inflammatory skin conditions like psoriasis. Breakthroughs in permeation enhancement technologies, especially oral d... -
Drug Discovery & DDS Weekly Report May 31, 2026
📄 Weekly Report May 31, 2026 (PDF) — Download Weekly Report May 31, 2026 (PDF) — DownloadDownload 🎙 Podcast May 31, 2026 (MP3) — Play & Download DrugDiscovery_DDSEnglishPodcast_20260531.mp3Download View Past Weekly Reports→
